Can Low LSD Doses Address Alzheimer’s Disease?
Eleusis Is Investigating Anti-Inflammatory Properties Of Psychedelics
The CEO of Eleusis tells Scrip how the privately held biotech plans to progress low-dose lysergic acid diethylamide (LSD) to both prevent and treat Alzheimer’s
You may also be interested in...
The effect of low-dose psilocybin, a compound found in mushrooms, on a rare debilitating condition, short-lasting unilateral neuralgiform headaches attacks, is to be evaluated by the 2019-founded UK biotech, Beckley Psytech.
COMPASS is testing a synthetic form of psilocybin, the active “magic mushroom” ingredient, in long-term depression patients, and thinks the capsule can be approved by 2025, its co-founder tells Scrip.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.